Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Krejci, Pavel ^a,b,c   Salazar, Lisa ^d   Kashiwada, Tamara A ^d   Chlebova, Katarina ^a   Salasova, Alena ^a   Thompson, Leslie Michels ^d   Bryja, Vitezslav ^a,b   Kozubik, Alois ^a,b   Wilcox, William R ^c,e  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; STAT1 PROTEIN; MUTANT PROTEIN;

ANIMAL CELL; ARTICLE; BONE DYSPLASIA; CARTILAGE CELL; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; MUTANT; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; BONE; CARTILAGE; CELL CULTURE; CELL FREE SYSTEM; CHO CELL; CRICETULUS; GENETICS; HAMSTER; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RAT;

ANIMALS; BONE AND BONES; BONE DISEASES, DEVELOPMENTAL; CARTILAGE; CELL-FREE SYSTEM; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HELA CELLS; HUMANS; MODELS, BIOLOGICAL; MUTANT PROTEINS; PHOSPHORYLATION; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 58149105445     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003961     Document Type: Article

References (33)

1. Passos-Bueno MR, Wilcox WR, Jabs EW, SertieéAli, Alonso LG, et al. (1999) Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 14: 115-125.
2. Horton WA, Hall JG, Hecht JT (2007) Achondroplasia. Lancet 370: 162-172.
3. Ornitz DM (2005) FGF signaling in the developing endochoodral skeleton. Cytokine Growth Factor Rev 16: 205-213.
4. L'Hôte CGM, Knowles MA (2605) Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp Cell Res 304: 417-431.
5. Su W-CS, Kitagawa M, Xue N, Xie B, Garofalo S, et al. (1997) Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386: 288-291.
6. Hart KC, Robertson SC, Donoghue DJ (2001) Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 12: 931-942.
7. Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P (2001) Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 20: 3553-3562.
8. Lievens PM-J, Mutinelli G, Baynes D, Liboi E (2004) The kinase activity of fibroblast growth factor receptor 3 with activation loop mutation affects receptor trafficking and signaling. J Biol Chem 279: 43254-43260.
9. Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA (2005) Sustained Erk1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PCI2 cells. Hum Mol Genet 14: 1529-1538.
10. Harada D, Yamanaka Y, Ueda K, Nishimura R, Morishima T (2007) Sustained phosphorylation of mutated FGFR3 is crucial feature of genetics dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCγ-activated STAT1. Bone 41: 273-281.
11. Krejci P, Kashiwada TA, Goodridge HS, Salazar L, Schibler M, et al. (2008) STAT1 and STAT3 do not participate in fibroblast growth factor-mediated growth arrest in chondrocytes. J Cell Sci 121: 272-281.
12. Cipl correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone 34: 26-36.
13. Li C, Chen L, Iwata T, Kitagawa M, Fu X, et al. (1999) A lys644glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet 8: 35-41.
14. Sahni M, Ambrosetti D, Mansukhani A, Gertner R, Levy D, et al. (1999) FGF signaling inhibits chondrocyte proliferation and regulares bone development through the STAT-1 pathway. Genes Dev 13: 1361-1366.
15. Sahni M, Raz R, Coffin JD, Levy D, Basilico C (2001) Stat1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development 128: 2119-2129.
16. Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, et al. (2001) Constitutive activation of MEK1 in chondrocytes causes Statl-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 18: 290-305.
17. Raucci A, Laplantine E, Masukhani A, Basilico C (2004) Activation of the Erk1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J Biol Chem 279: 1747-1756.
18. Krejci P, Bryja V, Pachernik J, Hampl A, Pogue R, et al. (2004) FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp Cell Res 297: 152-164.
19. Matsushita T, Wilcox WR, Ghan YY, Kawanami A, Bukulmez H, et al. (2008) FGFR3 promotes synchondrosis closure and fusion of ossilication centers through the MAPK pathway. Hum Mol Genet. In press.
20. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth-factor receptor 3. Nat Genet 12: 390-397.
21. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, et al. (2000) Transformation and Stat activation by derivatives of FGFRI, FGFR3, and FGFR4. Oncogene 19: 3309-3320.
22. Lievens PM-J, Liboi E (2003) The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J Biol Chem 278: 17344-17349.
23. Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, et al. (2007) Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gabl adaptor proteins. J Biol Chem 282: 2929-2936.
24. d'Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, et al. (1998) Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Diff 9: 71-78.
25. Webster MK, d'Avis PY, Robertson SG, Donoghue DJ (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16: 4081-4087.
26. Aikawa T, Segre GV, Lee K (2001) Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J Biol Chem 276; 29347-29352.
27. Rozenblatt-Rosen O, Mosonego-Ornan E, Sadot E, Madar-Shapiro L, Sheinin Y, et al. (2002) Induction of chondrocyte growth arrest by FGF: transcriptional and cytoskeletal alterations. J Cell Sci 115: 553-562.
28. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, et al. (2005) Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci 118: 5089-5100.
29. Dailey L, Laplantine E, Priore R, Basilico C (2003) A network of optional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J Cell Biol 161: 1053-1066.
30. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, et al. (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10: 80-86.
31. Legeai-Mallet L, Benoist-Lasselin C, Delezoide A, Munnich A, Bonaventure J (1998) Fibroblast growth factor receptor 3 mutation promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 273: 13007-13014.
32. Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, et al. (2000) Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 95: 992-998.
33. Aaronson DS, Horvath CM (2002) A road map for those who don't knowJAKSTAT. Science 296: 1653-1655.